News

Caretaker Medical Awarded the Grand Prize in NIH RADx Tech for Maternal Health Challenge

Caretaker Medical, a digital health company focused on developing hemodynamic monitoring devices, today announced that it has been awarded the $525,000 grand prize in the US National Institutes of Health (NIH) Rapid Acceleration of Diagnostics Technology for Maternal Health Challenge. The award recognizes Caretaker’s wireless, wearable wrist device, VitalStream, that can be used to monitor postpartum women for episodes of hyper- or hypotension, as well as detect the early onset of hemorrhage and sepsis. VitalStream continuously measures heart rate, blood pressure, respiration, cardiac output and stroke volume, among other vital signs.

In the US, over 80% of pregnancy-related deaths are preventable. And in 2020, 36% of deaths occurred 1-42 days postpartum. Continuous monitoring can help clinicians detect clinical decompensation sooner. A noninvasive, wireless monitor can expand advanced monitoring capabilities to more women and can potentially even be worn after hospital discharge.

“We are honored to receive this award and to be recognized for VitalStream’s potential to impact maternal health outcomes,” stated Jeff Pompeo, President and CEO of Caretaker Medical. “VitalStream can offer clinicians the continuous data they need to intervene earlier, potentially save the lives of new mothers.”

The RADx challenge prioritized technologies that are innovative, easy to use and can be used to help reduce health disparities.

For more information or to schedule a demonstration, contact Caretaker Medical.

Read more here.

Recent News

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin